Research programme: cancer therapeutics - Molecular Templates

Drug Profile

Research programme: cancer therapeutics - Molecular Templates

Alternative Names: 3F7; 5G2; MT 2289; MT 4019; MT-2274; MT-SAM3

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Molecular Templates
  • Developer Alnylam Pharmaceuticals; Eli Lilly; Enzon Pharmaceuticals; Molecular Templates
  • Class Antibodies; Bacterial toxins; Drug conjugates; Small interfering RNA
  • Mechanism of Action CD38 antigen inhibitors; ERBB 2 receptor antagonists; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Malignant melanoma; Multiple myeloma
  • Research Hodgkin's disease
  • No development reported Cancer; Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 14 Dec 2015 Early research in Hodgkin's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top